Protocol Ledger

NCT05203679 · Phase II/III · ACTIVE NOT RECRUITING

Evaluation of the Safety and Efficacy of Hemophilia B Gene Therapy Drug

Interventional Phase II/III clinical trial protocol NCT05203679 sponsored by Shanghai Xinzhi BioMed Co in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-12-30 Enrollment: 32 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05203679
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)32 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05203679
Protocol FieldVerified Registry Value
NCT IdentifierNCT05203679
Consolidated Lead SponsorShanghai Xinzhi BioMed Co
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase II/III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment32 participants (ACTUAL)
Registered Start Date2021-12-30
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05203679
Hospital Research SiteLocationSite Profile
Anhui Provincial HospitalHefei, ChinaOpen Hospital Dossier ->
Peking Union Medical College HospitalBeijing, ChinaOpen Hospital Dossier ->
Nanfang Hospital, Southern Medical UniversityGuangzhou, ChinaOpen Hospital Dossier ->
Henan Cancer HospitalZhengzhou, ChinaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI